RxDoctor Payments Data

Eugene Shin, MD

Family Medicine · Las Vegas, NVNPI 1306372255

Payments from drug & device makers

$1,767in general payments, 2019–2025

Across 84 payments — averaging $21.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$345
  • Novo Nordisk$258
  • AbbVie$152
  • Pfizer$130
  • Amgen$122
  • Intuitive Surgical$114
  • plus $646 from 16 others

What the payments were for

  • Food & beverage$1,74799%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,767 in reported general payments places this provider in the 75th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$105,486
Medicare patients
325
Services billed
1,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide35$36,357
FarxigaDapagliflozin Propanediol23$28,336
EliquisApixaban20$15,312
EucrisaCrisaborole13$9,755
Novofine 32Pen Needle, Diabetic13$796
Rosuvastatin Calcium27$683
Alendronate Sodium18$616
Atorvastatin Calcium78$575
Fluticasone Propionate61$459
Diltiazem Hcl12$444
Albuterol Sulfate HfaAlbuterol Sulfate13$376
Simvastatin40$376
Lisinopril39$270
Famotidine25$216
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$83$36,35735 claims
AstraZenecaFarxiga$345$28,33623 claims
PfizerEliquis, Eucrisa$130$25,06733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →